To Evaluate the Safety and PK Characteristics in Healthy Volunteers-JW24107
NCT ID: NCT06816719
Last Updated: 2025-02-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
47 participants
INTERVENTIONAL
2024-09-02
2024-11-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP0678, and the Effect of Food on ZSP0678 Pharmacokinetics
NCT04137055
Effect of Food on the Pharmacokinetics of TEW-7197 in Healthy Subjects
NCT03704675
A Study to Investigate the Safety, Tolerability, Food Effect, and Pharmacokinetics of JNJ-54416076 in Healthy Participants
NCT02670395
OPS-2071 Single and Multiple Dose Study to Investigate PK and PD Profile in Healthy Korean Male Subjects.
NCT01925521
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Male Volunteers.
NCT05407220
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Safety: All adverse events are summarized in terms of the number of subjects, expression rate, and number of expressions of adverse reactions by treatment group.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sequence 1
(Period 1/3: Treatment A) (Period 2/4: Treatment B)
Treatment A: JW0106 1 tablet + C2101 1 tablet Treatment B: JW0107 1 tablet
Treatment A: JW0106 1 tablet + C2101 1 tablet
* Co-administration of 1 tablet of JW0106 and 1 tablet of C2101
* Administration orally with 150 mL of water under fasting conditions
Treatment B: JW0107 1 tablet
* Administration alone of 1 tablet of JW0107
* Administration orally with 150 mL of water under fasting conditions
Sequence 2
(Period 1/3: Treatment B) (Period 2/4: Treatment A)
Treatment A: JW0106 1 tablet + C2101 1 tablet Treatment B: JW0107 1 tablet
Treatment A: JW0106 1 tablet + C2101 1 tablet
* Co-administration of 1 tablet of JW0106 and 1 tablet of C2101
* Administration orally with 150 mL of water under fasting conditions
Treatment B: JW0107 1 tablet
* Administration alone of 1 tablet of JW0107
* Administration orally with 150 mL of water under fasting conditions
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Treatment A: JW0106 1 tablet + C2101 1 tablet
* Co-administration of 1 tablet of JW0106 and 1 tablet of C2101
* Administration orally with 150 mL of water under fasting conditions
Treatment B: JW0107 1 tablet
* Administration alone of 1 tablet of JW0107
* Administration orally with 150 mL of water under fasting conditions
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
19 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
JW Pharmaceutical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Trial Center, Jeonbuk National University Hospital
Jeonju, Korea, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JW24107
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.